Webinar Overview

SGLT2 inhibitors reduce hyperglycemia by increasing glucose excretion into the urine. This class of drugs are commonly used for management of human type 2 diabetes mellitus. Two SGLT2 inhibitors have now been approved for treatment of feline diabetes mellitus. Widespread use of these drugs over the last year has increased our knowledge and experience with their use in cats. This lecture will review the mechanism of action, results of field studies, and current literature on the use of SGLT2 inhibitors in cats. The efficacy and adverse events reported in the pivotal field studies will be compared and contrasted to those reported in clinical veterinary medicine since drug approval. The lecture will also review recommendations for case selection, monitoring and management of adverse effects based on clinical experience in the last year

Learning objectives:

1. Upon completion, participant will gain insight into the mechanism of action of SGLT2 inhibitors in feline diabetes mellitus
2. Upon completion, participants will be able to identify, treat and understand common adverse events associated with SGLT2i use in feline diabetes mellitus
3. Upon completion, participant will be able to formulate potential on and off-label uses for SGLT2i in feline medicine and consider potential future applications of SGLT2i in veterinary medicine.